Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

MMP-14 Mediates Migration of Acute Myelogenous Leukemia Cells

Neeta Shirvaikar, MSc, Ali Jalili, MSc, PhD, Imran Mirza, FRCPC, Sara Ilnitsky, BSc, Chris Korol, Loree M. Larratt, MD, A. Robert Turner, MD, FRCPC, Anna Janowska-Wieczorek, MD, PhD

Blood (2008) 112 (11): 2943.

https://doi.org/10.1182/blood.V112.11.2943.2943

Published: 2008

Journal Articles

The Potent Deacetylase Inhibitor Trichostatin a (TSA) Increases CXCR4 Expression in Hematopoietic Stem/Progenitor Cells by Chromatin Remodelling

Hilal Gul, PhD, MSc, Leah A. Marquez-Curtis, PhD, BSc, Jennifer Lo, Nadia Jahroudi, PhD, A. Robert Turner, MD, FRCPC, Loree M. Larratt, MD, Anna Janowska-Wieczorek, MD, PhD

Blood (2008) 112 (11): 3487.

https://doi.org/10.1182/blood.V112.11.3487.3487

Published: 2008

Journal Articles

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

A. Robert Turner, MD, Joanne D Hewitt, BSN, NP, Anmmd Kamruzzaman, M.Sc, Loree M. Larratt, MD, Deborah A. Rusnak, BSN, Nanette Cox-Kennett, MSN, NP, Andrew R. Belch, MD

Blood (2008) 112 (11): 3237.

https://doi.org/10.1182/blood.V112.11.3237.3237

Published: 2008

Journal Articles

HyperCKemia in CML Patients on Imatinib Mesylate.

Joanne D. Hewitt, BScN, Deborah A. Rusnak, RN, Nanette Cox-Kennett, MN, Loree M. Larratt, MD, Robert Turner, MD

Blood (2007) 110 (11): 2965.

https://doi.org/10.1182/blood.V110.11.2965.2965

Published: 2007

Journal Articles

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

James A. Russell, FRCP, Leanne Kmet, MSc, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, Michelle Geddes, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Christopher Brown, MD, Jan Storek, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 5398.

https://doi.org/10.1182/blood.V108.11.5398.5398

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

James A. Russell, FRCP, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, M. Ahsan Chaudhry, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, Christopher Brown, MD, Alexander Balogh, MD, Jan Storek, MD, Michelle Geddes, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3009.

https://doi.org/10.1182/blood.V108.11.3009.3009

Published: 2006

Journal Articles

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Mary Lynn Savoie, MD, Alexander Balogh, MD, Ahsan Chaudhry, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD,PhD, Christopher Brown, MD,PhD, Diana Quinlan, RN, Leanne Kmet, PhD, Loree M. Larratt, MD, A. Robert Turner, MD, James A. Russell, FRCPE

Blood (2006) 108 (11): 3010.

https://doi.org/10.1182/blood.V108.11.3010.3010

Published: 2006

Journal Articles

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Loree M. Larratt, MD, Michelle Geddes, MD, Jan Storek, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3159.

https://doi.org/10.1182/blood.V108.11.3159.3159

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Michelle Geddes, MD, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Alexander Balogh, MD, Jan Storek, MD, Christopher Brown, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3140.

https://doi.org/10.1182/blood.V108.11.3140.3140

Published: 2006

Journal Articles

In Vitro Chemotactic Index and Response to CXCR4 Antagonist AMD3100 Correlate with CD34 + Cell Yield from Leukapheresis Products: Implications for Poor Mobilizers.

Leah A. Marquez-Curtis, PhD, Jencet Montano, BSc, Doris Quinn, RN, Loree M. Larratt, MD, A. Robert Turner, MD, Mariusz Ratajczak, MD, PhD, Anna Janowska-Wieczorek, MD, PhD

Blood (2006) 108 (11): 727.

https://doi.org/10.1182/blood.V108.11.727.727

Published: 2006

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

James A. Russell, FRCP, Loree M. Larratt, MD, A. Robert Turner, MD, M. Ahsan Chaudhry, MD, Oluyeme Jeje, MD, Donald Morris, MD, Christopher Brown, MD, Diana M. Quinlan, BN, Douglas A. Stewart, MD

Blood (2006) 108 (11): 2865.

https://doi.org/10.1182/blood.V108.11.2865.2865

Published: 2006

Journal Articles

Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Tranplantation — Evidence to Support the Existence of a Lymphoma Progenitor Cell.

Jason Hart, MD, A. Robert Turner, MD, Loree M. Larratt, MD, James A. Russell, MD, Bevin Franko, B.Sc., Christine Frantz, M.Sc, Teresa Paonessa, B.Sc, Adnan Mansoor, MD, M.Sc, Raymond Lai, MD, Ph.D

Blood (2006) 108 (11): 2415.

https://doi.org/10.1182/blood.V108.11.2415.2415

Published: 2006

Journal Articles

Stem Cell Mobilization and Egress of AML Blasts from the Bone Marrow Are Both Regulated by MT-MMP-Mediated Activation of MMP-2.

Leah A. Marquez-Curtis, PhD, Neeta Shirvaikar, MSc, Loree M. Larratt, MD, A. Robert Turner, MD, Mariusz Z. Ratajczak, MD, PhD, Anna Janowska-Wieczorek, MD, PhD

Blood (2005) 106 (11): 1368.

https://doi.org/10.1182/blood.V106.11.1368.1368

Published: 2005

Journal Articles

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Mary Lynn Savoie, MD, Alexander Balogh, MD, M. Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD, PhD, Christopher B. Brown, MD, PhD, Diana M. Quinlan, A. Robert Turner, MD, Loree M. Larratt, MD, James A. Russell, MBBChir, FRCPE

Blood (2005) 106 (11): 2733.

https://doi.org/10.1182/blood.V106.11.2733.2733

Published: 2005

Journal Articles

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

Jonathan J. Keats, Christopher A. Maxwell, Brian J. Taylor, Michael J. Hendzel, Marta Chesi, P. Leif Bergsagel, Loree M. Larratt, Michael J. Mant, Tony Reiman, Andrew R. Belch, Linda M. Pilarski

Blood (2005) 105 (10): 4060–4069.

https://doi.org/10.1182/blood-2004-09-3704

Published: 2005

Journal Articles

Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstrom’s Macroglobulinemia.

Sophia Adamia, Steven P. Treon, MD, Michael J. Mant, MD, Loree M. Larratt, MD, Tony Reiman, MD, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2004) 104 (11): 1363.

https://doi.org/10.1182/blood.V104.11.1363.1363

Published: 2004

Journal Articles

Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Kanti R. Rai, MD, Joseph O. Moore, MD, Thomas E. Boyd, MD, Loree M. Larratt, MD, Anatoliy K. Golenkov, MD, Benjamin Koziner, MD, Asher Chanan-Khan, MD, R. G. Bociek, MD, Loretta M. Itri, MD

Blood (2004) 104 (11): 338.

https://doi.org/10.1182/blood.V104.11.338.338

Published: 2004

Journal Articles

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

Jonathan J. Keats, Tony Reiman, Christopher A. Maxwell, Brian J. Taylor, Loree M. Larratt, Michael J. Mant, Andrew R. Belch, Linda M. Pilarski

Blood (2003) 101 (4): 1520–1529.

https://doi.org/10.1182/blood-2002-06-1675

Published: 2003

Journal Articles

Sensitivity of Acute Leukemia Cells to Cytarabine Is a Correlate of Cellular es Nucleoside Transporter Site Content Measured by Flow Cytometry With SAENTA-Fluorescein

Wendy P. Gati, Alan R.P. Paterson, Loree M. Larratt, A. Robert Turner, Andrew R. Belch

Blood (1997) 90 (1): 346–353.

https://doi.org/10.1182/blood.V90.1.346

Published: 1997

NARROW

MMP-14 Mediates Migration of Acute Myelogenous Leukemia Cells

The Potent Deacetylase Inhibitor Trichostatin a (TSA) Increases CXCR4 Expression in Hematopoietic Stem/Progenitor Cells by Chromatin Remodelling

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

HyperCKemia in CML Patients on Imatinib Mesylate.

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

In Vitro Chemotactic Index and Response to CXCR4 Antagonist AMD3100 Correlate with CD34 + Cell Yield from Leukapheresis Products: Implications for Poor Mobilizers.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Tranplantation — Evidence to Support the Existence of a Lymphoma Progenitor Cell.

Stem Cell Mobilization and Egress of AML Blasts from the Bone Marrow Are Both Regulated by MT-MMP-Mediated Activation of MMP-2.

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstrom’s Macroglobulinemia.

Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

Sensitivity of Acute Leukemia Cells to Cytarabine Is a Correlate of Cellular es Nucleoside Transporter Site Content Measured by Flow Cytometry With SAENTA-Fluorescein

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only